Transarterial Infusion Of Bevacizumab Combined With TACE For The Treatment Of TACE-refractory HCC:Therapeutic Analysis Of 13 Cases

Objective:To investigate the safety and efficacy of transarterial infusion of bevacizumab combined with transcatheter arterial chemoembolization(TACE) in treating TACE-refractory hepatocellular carcinoma (HCC). Methods:During the period from October 2012 to September 2013 at author’s hospital, a total of 584 patients underwent TACE. Of the 584 patients, TACE-refractory HCC was observed in 13. Then transarterial infusion of bevacizumab together with conventional TACE was carried out in these patients. After the treatment the tumor response was evaluated according to the modified response evaluation criteria in solid tumors (mRECIST). The patient’s physical ability scores and liver functions were determined before and after the treatment. Progression free survival time and overall survival time were recorded. The results were analyzed. Results:Of the 13 patients, partial response was obtained in 2, stable disease in 8 and progressive disease in 3. Improvement of patient’s physical ability scores was observed in 6 patients, and improved liver function was seen in 6 patients. The median progression free survival time and overall survival time were 356.5 days and 410.0 days respectively. No procedure related death or severe complications occurred. Conclusions: For the treatment of TACE-refractory HCC, transarterial infusion of bevacizumab combined with conventional TACE is safe and effective.